IL18 and acute respiratory distress syndrome: On a relevant note, given the occurrence of acute respiratory distress syndrome (ARDS) in COVID-19 patients, it is of interest that a retrospective analysis of an RCT including 683 subjects with infection-related acute respiratory distress syndrome (ARDS) found that rosuvastatin administration was associated with increased interleukin-18 plasma levels, which were tied to higher mortality [70].